QNTM
Quantum BioPharma Ltd.
Price Chart
Latest Quote
$3.80
-0.17 (-4.28%)
Current Price
| Previous Close | $3.97 |
| Open | $3.98 |
| Day High | $4.09 |
| Day Low | $3.70 |
| Volume | 166,356 |
Stock Information
| Shares Outstanding | 6.40M |
| Total Debt | $870K |
| Cash Equivalents | $4.56M |
| Net Income | $-31.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $24.31M |
| EPS (TTM) | $-7.67 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $18.60M |
| Income | $-31.16M |
| Book/sh | $0.10 |
| Cash/sh | $0.71 |
Financial Ratios
| Quick Ratio | 0.29 |
| Current Ratio | 0.63 |
Returns & Margins
| ROA | -62.38% |
| ROE | -2056.51% |
Ownership
| Insider Ownership | 12.36% |
| Institutional Ownership | 9.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.49 |
| P/B | 37.25 |
Analyst Data
| Recommendation | none |
| Target Price | $12.31 |
Technical Indicators
| SMA20 | $5.22 |
| SMA50 | $4.93 |
| SMA200 | $7.85 |
| RSI | 11.17 |
| ATR | 0.5815 |
| Shares Float | 5.93M |
| Short Float | 7.10% |
| Short Ratio | 0.93 |
| Volatility | 0.40 |
| Rel Volume | 0.38 |
Performance History
| Week | -5.00% |
| Month | -45.71% |
| Quarter | +61.02% |
| 6 Months | -56.07% |
| YTD | -45.79% |
| Year | -85.23% |
| 3 Years | -94.87% |
| 5 Years | -96.99% |
| 10 Years | -99.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.80 | 166,400 |
| 2026-06-17 | $3.97 | 245,500 |
| 2026-06-16 | $3.64 | 95,700 |
| 2026-06-15 | $3.70 | 171,200 |
| 2026-06-12 | $3.83 | 118,200 |
| 2026-06-11 | $4.00 | 194,900 |
| 2026-06-10 | $3.93 | 187,600 |
| 2026-06-09 | $3.89 | 322,000 |
| 2026-06-08 | $4.05 | 264,900 |
| 2026-06-05 | $4.26 | 382,600 |
| 2026-06-04 | $4.48 | 586,500 |
| 2026-06-03 | $4.88 | 356,300 |
| 2026-06-02 | $5.11 | 609,000 |
| 2026-06-01 | $5.25 | 698,300 |
| 2026-05-29 | $6.86 | 187,700 |
| 2026-05-28 | $7.02 | 542,500 |
| 2026-05-27 | $7.64 | 550,400 |
| 2026-05-26 | $7.05 | 1,778,300 |
| 2026-05-22 | $9.24 | 830,500 |
| 2026-05-21 | $7.81 | 478,900 |
| 2026-05-20 | $7.81 | 476,300 |
| 2026-05-19 | $7.00 | 335,600 |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
đ° Latest News
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH
MT Newswires âĸ 2026-05-19T11:21:55ZQuantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)
InvestorsHub âĸ 2026-05-18T14:37:38Z
Quantum Biopharma Set Oct. 27 as Record Date For CVRs Distribution Tied to Future Settlement Proceeds
MT Newswires âĸ 2025-10-03T12:45:49ZQuantum BioPharma Provides "Promising" Results From Study With Massachusetts General Hospital; Shares Rise
MT Newswires âĸ 2025-08-08T13:47:35ZQuantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Benzinga âĸ 2025-08-05T18:25:21Z
Quantum Biopharma Confirms No Safety, Tolerability Concerns in Phase 1 Lucid-MS Dosing Trial
MT Newswires âĸ 2025-08-05T12:14:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $618,640 | $47,577 | $299 | $48,822 |
| Total Expenses | $15,317,409 | $15,884,034 | $19,570,114 | $27,429,611 |
| Other Income Expense | $-11,256,875 | $443,191 | $553,462 | $407,036 |
| Other Non Operating Income Expenses | $456,213 | $3,989 | $4,939,015 | $119,453 |
| Net Non Operating Interest Income Expense | $-382,556 | $525,314 | $786,064 | $318,913 |
| Interest Expense Non Operating | $618,640 | $47,577 | $299 | $48,822 |
| Operating Expense | $15,317,409 | $15,884,034 | $19,570,114 | $27,429,611 |
| General And Administrative Expense | $12,008,455 | $9,310,085 | $13,204,620 | $15,981,352 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,175,286 | $-14,202,724 | $-17,902,179 | $-26,703,662 |
| Net Interest Income | $-382,556 | $525,314 | $786,064 | $318,913 |
| Interest Income | $236,084 | $572,891 | $786,363 | $367,735 |
| Normalized Income | $-14,462,198 | $-14,641,926 | $-13,516,626 | $-26,991,245 |
| Net Income From Continuing And Discontinued Operation | $-26,175,286 | $-14,202,724 | $-17,902,179 | $-23,606,828 |
| Total Operating Income As Reported | $-15,302,374 | $-16,136,260 | $-23,789,498 | $-27,429,611 |
| Net Income Common Stockholders | $-26,175,286 | $-14,202,724 | $-17,902,179 | $-23,606,828 |
| Net Income | $-26,175,286 | $-14,202,724 | $-17,902,179 | $-23,606,828 |
| Net Income Including Noncontrolling Interests | $-26,956,840 | $-14,915,529 | $-18,230,588 | $-23,606,828 |
| Net Income Continuous Operations | $-26,956,840 | $-14,915,529 | $-18,230,588 | $-26,703,662 |
| Pretax Income | $-26,956,840 | $-14,915,529 | $-18,230,588 | $-26,703,662 |
| Special Income Charges | $43,336 | $732,417 | $-4,555,805 | $0 |
| Interest Income Non Operating | $236,084 | $572,891 | $786,363 | $367,735 |
| Operating Income | $-15,317,409 | $-15,884,034 | $-19,570,114 | $-27,429,611 |
| Depreciation Amortization Depletion Income Statement | $545,780 | $490,571 | $2,506,316 | $4,537,415 |
| Depreciation And Amortization In Income Statement | $545,780 | $490,571 | $2,506,316 | $4,537,415 |
| Net Income Discontinuous Operations | - | $0 | $0 | $3,096,834 |
| Per Share | ||||
| Diluted EPS | $-8.20 | $-13.12 | $-29.93 | $-39.61 |
| Basic EPS | $-8.20 | $-13.12 | $-29.93 | $-39.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-14,079,332 | $-14,816,583 | $-11,338,420 | $-22,405,008 |
| Total Unusual Items | $-11,713,088 | $439,202 | $-4,385,553 | $287,583 |
| Total Unusual Items Excluding Goodwill | $-11,713,088 | $439,202 | $-4,385,553 | $287,583 |
| Reconciled Depreciation | $545,780 | $490,571 | $2,506,316 | $4,534,586 |
| EBITDA (Bullshit earnings) | $-25,792,420 | $-14,377,381 | $-15,723,973 | $-22,117,425 |
| EBIT | $-26,338,200 | $-14,867,952 | $-18,230,289 | $-26,654,840 |
| Diluted Average Shares | $3,285,876 | $1,136,922 | $609,056 | $595,883 |
| Basic Average Shares | $3,285,876 | $1,136,922 | $609,056 | $595,883 |
| Diluted NI Availto Com Stockholders | $-26,175,286 | $-14,202,724 | $-17,902,179 | $-23,606,828 |
| Minority Interests | $781,554 | $712,805 | $328,409 | $0 |
| Other Special Charges | $-43,336 | $-732,417 | - | - |
| Impairment Of Capital Assets | $0 | $0 | $4,555,805 | $0 |
| Gain On Sale Of Security | $-11,756,424 | $-293,215 | $170,252 | $287,583 |
| Research And Development | $2,763,174 | $6,083,378 | $3,859,178 | $6,910,844 |
| Selling General And Administration | $12,008,455 | $9,310,085 | $13,204,620 | $15,981,352 |
| Other Gand A | $6,858,634 | $6,499,507 | $7,514,058 | $14,450,094 |
| Salaries And Wages | $5,149,821 | $2,810,578 | $5,690,562 | $1,531,258 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,411,268 | $6,546,667 | $7,881,076 | $18,501,931 |
| Total Assets | $11,160,909 | $17,119,224 | $17,474,828 | $38,410,656 |
| Total Non Current Assets | $4,682,556 | $5,066,477 | $6,389,523 | $20,560,482 |
| Goodwill And Other Intangible Assets | $4,513,207 | $4,933,871 | $5,355,687 | $12,040,289 |
| Other Intangible Assets | $4,513,207 | $4,933,871 | $5,355,687 | $12,040,289 |
| Current Assets | $6,478,353 | $12,052,747 | $11,085,305 | $17,850,174 |
| Other Current Assets | $2,213,575 | $861,230 | - | - |
| Restricted Cash | $1,601,865 | $0 | - | - |
| Prepaid Assets | $15,290 | $69,036 | $155,413 | $472,137 |
| Inventory | $52,133 | $117,242 | $0 | - |
| Receivables | $231,053 | $3,807,018 | $7,416,752 | $374,377 |
| Other Receivables | $54,764 | $7,042 | $3,703 | - |
| Taxes Receivable | $102,714 | $367,480 | $209,550 | $279,333 |
| Accrued Interest Receivable | $73,575 | $156 | $15,511 | $95,044 |
| Loans Receivable | $0 | $3,432,340 | $7,187,988 | $0 |
| Cash Cash Equivalents And Short Term Investments | $2,364,437 | $7,198,221 | $3,513,140 | $17,003,660 |
| Cash And Cash Equivalents | $1,905,357 | $5,995,872 | $2,757,040 | $16,980,472 |
| Non Current Note Receivables | - | $0 | $907,366 | $7,431,656 |
| Investmentin Financial Assets | - | $2,224 | $6,049 | - |
| Non Current Accounts Receivable | - | - | $907,366 | - |
| Assets Held For Sale Current | - | - | - | $0 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $1,876,211 | $824,922 | $339,199 | $516,423 |
| Current Debt And Capital Lease Obligation | $1,876,211 | $824,922 | $339,199 | $478,419 |
| Current Debt | $1,773,046 | $771,142 | $300,549 | $300,549 |
| Other Current Borrowings | $472,497 | $152,113 | - | - |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $38,004 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,058,294 | $6,678,992 | $4,565,566 | $7,868,436 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $38,004 |
| Current Liabilities | $6,058,294 | $6,678,992 | $4,565,566 | $7,830,432 |
| Current Deferred Liabilities | $0 | $1,000,000 | $0 | - |
| Current Notes Payable | $1,300,549 | $619,029 | $300,549 | $300,549 |
| Payables And Accrued Expenses | $4,182,083 | $4,362,068 | $4,195,029 | $7,108,419 |
| Interest Payable | $409,193 | $409,193 | $409,193 | $409,193 |
| Payables | $1,981,851 | $3,254,838 | $3,240,658 | $2,760,002 |
| Accounts Payable | $1,981,851 | $3,254,838 | $3,240,658 | $2,760,002 |
| Other Current Liabilities | - | $492,002 | $31,338 | $243,594 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $6,924,475 | $11,480,538 | $13,236,763 | $30,542,220 |
| Total Equity Gross Minority Interest | $5,102,615 | $10,440,232 | $12,909,262 | $30,542,220 |
| Stockholders Equity | $6,924,475 | $11,480,538 | $13,236,763 | $30,542,220 |
| Other Equity Interest | $10,009 | $1,997,759 | $2,723,356 | $2,142,400 |
| Gains Losses Not Affecting Retained Earnings | $91,533 | $50,795 | $417,341 | $652,601 |
| Retained Earnings | $-198,286,170 | $-172,110,884 | $-157,908,160 | $-144,164,265 |
| Other | ||||
| Ordinary Shares Number | $3,887,771 | $2,299,514 | $605,796 | $592,373 |
| Share Issued | $3,887,771 | $2,299,514 | $605,796 | $592,373 |
| Tangible Book Value | $2,411,268 | $6,546,667 | $7,881,076 | $18,501,931 |
| Invested Capital | $8,697,521 | $12,251,680 | $13,537,312 | $30,842,769 |
| Working Capital | $420,059 | $5,373,755 | $6,519,739 | $10,019,742 |
| Capital Lease Obligations | $103,165 | $53,780 | $38,650 | $215,874 |
| Total Capitalization | $6,924,475 | $11,480,538 | $13,236,763 | $30,542,220 |
| Minority Interest | $-1,821,860 | $-1,040,306 | $-327,501 | $0 |
| Foreign Currency Translation Adjustments | $91,533 | $50,795 | $417,341 | $652,601 |
| Additional Paid In Capital | $35,405,812 | $31,072,543 | $30,225,741 | $28,500,924 |
| Capital Stock | $169,703,291 | $150,470,325 | $137,778,485 | $143,410,560 |
| Common Stock | $169,703,291 | $150,470,325 | $137,778,485 | $143,410,560 |
| Current Deferred Revenue | $0 | $1,000,000 | $0 | - |
| Current Capital Lease Obligation | $103,165 | $53,780 | $38,650 | $177,870 |
| Current Accrued Expenses | $2,200,232 | $1,107,230 | $954,371 | $4,348,417 |
| Investments And Advances | $0 | $2,224 | $6,049 | $827,612 |
| Other Investments | $0 | $2,224 | $6,049 | $827,612 |
| Net PPE | $169,349 | $130,382 | $120,421 | $260,925 |
| Gross PPE | $169,349 | $130,382 | $120,421 | $260,925 |
| Other Properties | $169,349 | $130,382 | $120,421 | $260,925 |
| Finished Goods | $18,306 | $65,269 | - | - |
| Raw Materials | $33,827 | $51,973 | - | - |
| Other Short Term Investments | $459,080 | $1,202,349 | $756,100 | $23,188 |
| Available For Sale Securities | - | $2,224 | $6,049 | - |
| Treasury Shares Number | - | - | $0 | - |
| Long Term Capital Lease Obligation | - | - | $0 | $38,004 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,237,012 | $-6,876,479 | $-10,827,264 | $-28,697,231 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,237,012 | $-6,876,479 | $-10,827,264 | $-28,333,273 |
| Cash Flow From Continuing Operating Activities | $-8,237,012 | $-6,876,479 | $-10,827,264 | $-27,190,291 |
| Operating Gains Losses | $10,595,884 | $-2,529,742 | $-5,534,785 | $292,838 |
| Cash From Discontinued Operating Activities | - | $0 | $0 | $-1,142,982 |
| Investing Activities | ||||
| Investing Cash Flow | $-1,952,469 | $-1,503,559 | $-269,579 | $12,123,408 |
| Cash Flow From Continuing Investing Activities | $-1,952,469 | $-1,503,559 | $-269,579 | $-607,534 |
| Cash From Discontinued Investing Activities | - | $0 | $0 | $12,730,942 |
| Capital Expenditure | - | - | - | $-363,958 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-2,957,816 | $-1,926,237 |
| Issuance Of Capital Stock | $338,331 | $10,670,618 | $34 | $0 |
| Financing Cash Flow | $6,098,966 | $11,618,870 | $-3,126,589 | $-2,069,308 |
| Cash Flow From Continuing Financing Activities | $6,098,966 | $11,618,870 | $-3,126,589 | $-2,069,308 |
| Net Other Financing Charges | $326,603 | - | - | - |
| Net Common Stock Issuance | $338,331 | $10,670,618 | $-2,957,782 | $-1,926,237 |
| Common Stock Issuance | $338,331 | $10,670,618 | $34 | $0 |
| Cash From Discontinued Financing Activities | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-113,862 | $-63,586 | $-189,054 | $-143,071 |
| Issuance Of Debt | $5,356,551 | $1,011,838 | $0 | $0 |
| End Cash Position | $1,905,357 | $5,995,872 | $2,757,040 | $16,980,472 |
| Beginning Cash Position | $5,995,872 | $2,757,040 | $16,980,472 | $35,259,645 |
| Changes In Cash | $-4,090,515 | $3,238,832 | $-14,223,432 | $-18,279,173 |
| Proceeds From Stock Option Exercised | $191,343 | $0 | $20,247 | $0 |
| Common Stock Payments | $0 | $0 | $-2,957,816 | $-1,926,237 |
| Net Issuance Payments Of Debt | $5,242,689 | $948,252 | $-189,054 | $-143,071 |
| Net Short Term Debt Issuance | $5,356,551 | $1,011,838 | $0 | $0 |
| Short Term Debt Issuance | $5,356,551 | $1,011,838 | $0 | $0 |
| Net Long Term Debt Issuance | $-113,862 | $-63,586 | $-189,054 | $-143,071 |
| Long Term Debt Payments | $-113,862 | $-63,586 | $-189,054 | $-143,071 |
| Net Investment Purchase And Sale | $-1,952,469 | $-1,503,559 | $-301,362 | $-243,576 |
| Sale Of Investment | $4,142,432 | $6,189,077 | $443,138 | $158,036 |
| Purchase Of Investment | $-6,094,901 | $-7,692,636 | $-744,500 | $-401,612 |
| Net Business Purchase And Sale | $0 | $0 | $31,783 | $0 |
| Sale Of Business | $0 | $0 | $31,783 | $0 |
| Change In Working Capital | $1,985,030 | $9,756,632 | $1,637,800 | $-7,120,329 |
| Change In Other Working Capital | $-1,000,000 | $1,000,000 | - | - |
| Change In Payables And Accrued Expense | $1,178,497 | $4,270,397 | $2,049,799 | $-699,778 |
| Change In Payable | $1,178,497 | $4,270,397 | $2,049,799 | $-699,778 |
| Change In Prepaid Assets | $53,746 | $86,377 | $316,724 | $795,930 |
| Change In Inventory | $65,109 | $-117,242 | $0 | $0 |
| Change In Receivables | $1,687,678 | $4,517,100 | $-728,723 | $-7,216,481 |
| Other Non Cash Items | $2,133,725 | $23,903 | $24,288 | $40,792 |
| Stock Based Compensation | $2,945,502 | $152,214 | $3,835,475 | $1,531,258 |
| Unrealized Gain Loss On Investment Securities | $513,907 | $145,472 | $378,425 | $234,226 |
| Asset Impairment Charge | $0 | $0 | $4,555,805 | $0 |
| Depreciation Amortization Depletion | $545,780 | $490,571 | $2,506,316 | $4,534,586 |
| Depreciation And Amortization | $545,780 | $490,571 | $2,506,316 | $4,534,586 |
| Gain Loss On Investment Securities | $11,140,416 | $-104,483 | $-5,151,271 | $-641,262 |
| Net Foreign Currency Exchange Gain Loss | $-501,196 | $-1,692,842 | $-383,514 | $934,100 |
| Net Income From Continuing Operations | $-26,956,840 | $-14,915,529 | $-18,230,588 | $-26,703,662 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-250,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-250,000 |
| Net PPE Purchase And Sale | - | $0 | $0 | $-113,958 |
| Purchase Of PPE | - | $0 | $0 | $-113,958 |
| Short Term Debt Payments | - | - | $0 | $0 |
| Depreciation | - | - | - | - |
Fetched: 2026-06-19